David M. Rubenstein
Known title: DirectorCIK: 0001543895
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MRNA hits 52-week high after Goldman raises target. The stock reached a new 52‑week high after Goldman Sachs increased its price target, citing upcoming melanoma data. This move aligns with a broader rotation of capital into healthcare names, lifting Moderna by about 6% and pushing the share price near the top of its 52‑week range. Analyst coverage shows an average target of $122.67, while recent commentary highlights interest in cancer vaccine developments.
Transaction History
| CG | ▼ Sell | Open Market | 400,000 | $17.1M | 9/11/2026 | View on chart |
| CG | ▼ Sell | Gift | 100,000 | $0 | 9/11/2026 | View on chart |
| MRNA | ▲ Buy | Option Exercise | 8,116 | — | 4/30/2026 | View on chart |
| CG | ▼ Sell | Gift | 100,000 | $0 | 3/19/2026 | View on chart |
| CG | ▼ Sell | Open Market | 500,000 | $23.3M | 3/19/2026 | View on chart |
| CG | ▼ Sell | Gift | 625,000 | $0 | 12/10/2025 | View on chart |
| CG | ▼ Sell | Open Market | 625,000 | $35.3M | 12/10/2025 | View on chart |
| MRNA | ▲ Buy | Option Exercise | 850 | — | 8/5/2025 | View on chart |
| MRNA | ▲ Buy | Option Exercise | 677 | — | 4/30/2025 | View on chart |
| CG | ▼ Sell | Open Market | 2,000,000 | $77.3M | 6/6/2022 | View on chart |
| CG | ▼ Sell | Open Market | 2,000,000 | $116.0M | 11/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Carlyle Schedules Q3 Earnings as Shares Fall and Targets Cut
Carlyle Secured Lending has scheduled its Q3 earnings release and conference call for the quarter ended September 30, 2026. In recent trading, the company's shares fell, as reported in a market roundup. Analysts at UBS and TD Cowen lowered their price targets to $60 and $42, citing concerns such as the risk of private‑credit exposure to a growing AI financing wave that Carlyle highlighted.
Carlyle Schedules Q3 Earnings as Shares Fall and Targets Cut. Carlyle Secured Lending has scheduled its Q3 earnings release and conference call for the quarter ended September 30, 2026. In recent trading, the company's shares fell, as reported in a market roundup. Analysts at UBS and TD Cowen lowered their price targets to $60 and $42, citing concerns such as the risk of private‑credit exposure to a growing AI financing wave that Carlyle highlighted.